Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer

F. Patrone, A. Ballestrero, F. Ferrando, F. Brema, L. Moraglio, M. Valbonesi, P. Basta, R. Ghio, M. Gobbi, M. Sessarego

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: High-dose chemotherapy produces high complete remission (CR) rates and some survival advantage in patients with metastatic breast cancer (BC). A current issue is the possibility that these patients may have an even better prognosis with multiple high-dose treatments. In this study, we evaluated the feasibility of a four-step, high-dose sequential chemotherapy (HDSC) with double autologous hematopoietic progenitor-cell rescue. We also tested the hypothesis that peripheral-blood progenitor cells (PBPCs) harvested following a single recruitment with cyclophosphamide (CY) and granulocyte-macrophage colony-stimulating factor (GM-CSF) allow the safe administration of the whole HDSC with closely timed repeated courses of several non-cross-resistant agents. Patients and Methods: The treatment plan included CY 7 g/m2, followed by GM-CSF 5 to 7 μg/kg/d administered by continuous intravenous (IV) infusion on days 2 to 14; PBPCs with or without bone marrow (BM) harvest; mitoxantrone (NOV) 60, 75, or 90 mg/m2 plus melphalan (L-PAM) 140 to 180 mg/m2 with hematopoietic rescue; methotrexate (MTX) 8 g/m2 plus vincristine (VCR) 1.4 mg/m2; and etoposide (VP-16) 1.5 g/m2 plus carboplatin (PP) 1.5 g/m2 with hematopoietic rescue. Results: All 15 patients enrolled completed the entire treatment and there were no toxic deaths. Hematologic reconstitution was good at each step. The median number of days with an absolute neutrophil count (ANC) less than 100/μL and platelet count less than 20,000/μL were 8 and 3, respectively, after NOV plus L-PAM, and 7 and 4, respectively, after VP-16 plus PP. The main nonhematologic toxicity was mucositis, while organ toxicity was mild and reversible. Conclusion: This regimen is feasible, with acceptable toxicity. GM-CSF and PBPCs have a pivotal role, as they hasten hematologic reconstitution, abate toxicity, and allow rapid recycling.

Original languageEnglish
Pages (from-to)840-846
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number4
Publication statusPublished - 1995

Fingerprint

Hematopoietic Stem Cells
Melphalan
Etoposide
Granulocyte-Macrophage Colony-Stimulating Factor
Breast Neoplasms
Drug Therapy
Blood Cells
Stem Cells
Cyclophosphamide
Mitoxantrone
Mucositis
Poisons
Carboplatin
Recycling
Vincristine
Platelet Count
Intravenous Infusions
Methotrexate
Neutrophils
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Patrone, F., Ballestrero, A., Ferrando, F., Brema, F., Moraglio, L., Valbonesi, M., ... Sessarego, M. (1995). Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. Journal of Clinical Oncology, 13(4), 840-846.

Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. / Patrone, F.; Ballestrero, A.; Ferrando, F.; Brema, F.; Moraglio, L.; Valbonesi, M.; Basta, P.; Ghio, R.; Gobbi, M.; Sessarego, M.

In: Journal of Clinical Oncology, Vol. 13, No. 4, 1995, p. 840-846.

Research output: Contribution to journalArticle

Patrone, F, Ballestrero, A, Ferrando, F, Brema, F, Moraglio, L, Valbonesi, M, Basta, P, Ghio, R, Gobbi, M & Sessarego, M 1995, 'Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer', Journal of Clinical Oncology, vol. 13, no. 4, pp. 840-846.
Patrone, F. ; Ballestrero, A. ; Ferrando, F. ; Brema, F. ; Moraglio, L. ; Valbonesi, M. ; Basta, P. ; Ghio, R. ; Gobbi, M. ; Sessarego, M. / Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 4. pp. 840-846.
@article{40b7ef10bb3448799f8b0fd66bde1fae,
title = "Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer",
abstract = "Purpose: High-dose chemotherapy produces high complete remission (CR) rates and some survival advantage in patients with metastatic breast cancer (BC). A current issue is the possibility that these patients may have an even better prognosis with multiple high-dose treatments. In this study, we evaluated the feasibility of a four-step, high-dose sequential chemotherapy (HDSC) with double autologous hematopoietic progenitor-cell rescue. We also tested the hypothesis that peripheral-blood progenitor cells (PBPCs) harvested following a single recruitment with cyclophosphamide (CY) and granulocyte-macrophage colony-stimulating factor (GM-CSF) allow the safe administration of the whole HDSC with closely timed repeated courses of several non-cross-resistant agents. Patients and Methods: The treatment plan included CY 7 g/m2, followed by GM-CSF 5 to 7 μg/kg/d administered by continuous intravenous (IV) infusion on days 2 to 14; PBPCs with or without bone marrow (BM) harvest; mitoxantrone (NOV) 60, 75, or 90 mg/m2 plus melphalan (L-PAM) 140 to 180 mg/m2 with hematopoietic rescue; methotrexate (MTX) 8 g/m2 plus vincristine (VCR) 1.4 mg/m2; and etoposide (VP-16) 1.5 g/m2 plus carboplatin (PP) 1.5 g/m2 with hematopoietic rescue. Results: All 15 patients enrolled completed the entire treatment and there were no toxic deaths. Hematologic reconstitution was good at each step. The median number of days with an absolute neutrophil count (ANC) less than 100/μL and platelet count less than 20,000/μL were 8 and 3, respectively, after NOV plus L-PAM, and 7 and 4, respectively, after VP-16 plus PP. The main nonhematologic toxicity was mucositis, while organ toxicity was mild and reversible. Conclusion: This regimen is feasible, with acceptable toxicity. GM-CSF and PBPCs have a pivotal role, as they hasten hematologic reconstitution, abate toxicity, and allow rapid recycling.",
author = "F. Patrone and A. Ballestrero and F. Ferrando and F. Brema and L. Moraglio and M. Valbonesi and P. Basta and R. Ghio and M. Gobbi and M. Sessarego",
year = "1995",
language = "English",
volume = "13",
pages = "840--846",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer

AU - Patrone, F.

AU - Ballestrero, A.

AU - Ferrando, F.

AU - Brema, F.

AU - Moraglio, L.

AU - Valbonesi, M.

AU - Basta, P.

AU - Ghio, R.

AU - Gobbi, M.

AU - Sessarego, M.

PY - 1995

Y1 - 1995

N2 - Purpose: High-dose chemotherapy produces high complete remission (CR) rates and some survival advantage in patients with metastatic breast cancer (BC). A current issue is the possibility that these patients may have an even better prognosis with multiple high-dose treatments. In this study, we evaluated the feasibility of a four-step, high-dose sequential chemotherapy (HDSC) with double autologous hematopoietic progenitor-cell rescue. We also tested the hypothesis that peripheral-blood progenitor cells (PBPCs) harvested following a single recruitment with cyclophosphamide (CY) and granulocyte-macrophage colony-stimulating factor (GM-CSF) allow the safe administration of the whole HDSC with closely timed repeated courses of several non-cross-resistant agents. Patients and Methods: The treatment plan included CY 7 g/m2, followed by GM-CSF 5 to 7 μg/kg/d administered by continuous intravenous (IV) infusion on days 2 to 14; PBPCs with or without bone marrow (BM) harvest; mitoxantrone (NOV) 60, 75, or 90 mg/m2 plus melphalan (L-PAM) 140 to 180 mg/m2 with hematopoietic rescue; methotrexate (MTX) 8 g/m2 plus vincristine (VCR) 1.4 mg/m2; and etoposide (VP-16) 1.5 g/m2 plus carboplatin (PP) 1.5 g/m2 with hematopoietic rescue. Results: All 15 patients enrolled completed the entire treatment and there were no toxic deaths. Hematologic reconstitution was good at each step. The median number of days with an absolute neutrophil count (ANC) less than 100/μL and platelet count less than 20,000/μL were 8 and 3, respectively, after NOV plus L-PAM, and 7 and 4, respectively, after VP-16 plus PP. The main nonhematologic toxicity was mucositis, while organ toxicity was mild and reversible. Conclusion: This regimen is feasible, with acceptable toxicity. GM-CSF and PBPCs have a pivotal role, as they hasten hematologic reconstitution, abate toxicity, and allow rapid recycling.

AB - Purpose: High-dose chemotherapy produces high complete remission (CR) rates and some survival advantage in patients with metastatic breast cancer (BC). A current issue is the possibility that these patients may have an even better prognosis with multiple high-dose treatments. In this study, we evaluated the feasibility of a four-step, high-dose sequential chemotherapy (HDSC) with double autologous hematopoietic progenitor-cell rescue. We also tested the hypothesis that peripheral-blood progenitor cells (PBPCs) harvested following a single recruitment with cyclophosphamide (CY) and granulocyte-macrophage colony-stimulating factor (GM-CSF) allow the safe administration of the whole HDSC with closely timed repeated courses of several non-cross-resistant agents. Patients and Methods: The treatment plan included CY 7 g/m2, followed by GM-CSF 5 to 7 μg/kg/d administered by continuous intravenous (IV) infusion on days 2 to 14; PBPCs with or without bone marrow (BM) harvest; mitoxantrone (NOV) 60, 75, or 90 mg/m2 plus melphalan (L-PAM) 140 to 180 mg/m2 with hematopoietic rescue; methotrexate (MTX) 8 g/m2 plus vincristine (VCR) 1.4 mg/m2; and etoposide (VP-16) 1.5 g/m2 plus carboplatin (PP) 1.5 g/m2 with hematopoietic rescue. Results: All 15 patients enrolled completed the entire treatment and there were no toxic deaths. Hematologic reconstitution was good at each step. The median number of days with an absolute neutrophil count (ANC) less than 100/μL and platelet count less than 20,000/μL were 8 and 3, respectively, after NOV plus L-PAM, and 7 and 4, respectively, after VP-16 plus PP. The main nonhematologic toxicity was mucositis, while organ toxicity was mild and reversible. Conclusion: This regimen is feasible, with acceptable toxicity. GM-CSF and PBPCs have a pivotal role, as they hasten hematologic reconstitution, abate toxicity, and allow rapid recycling.

UR - http://www.scopus.com/inward/record.url?scp=0028957912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028957912&partnerID=8YFLogxK

M3 - Article

C2 - 7707109

AN - SCOPUS:0028957912

VL - 13

SP - 840

EP - 846

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -